Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.41 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 5/20 | 0.38 |
| ▸ | JAK3 | P52333 | 5/20 | 0.38 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843649 | 0.90 | SYK (0.47) | SYKJAK2JAK3FLT3TRPV1 | |
| SCHEMBL2446453 | 0.89 | TNK2 (0.48) | SYKKCNH3JAK2TNK2TYK2 | |
| SCHEMBL2448060 | 0.88 | TRPV1 (0.40) | SYKKCNH3JAK2TNK2TYK2 | |
| SCHEMBL2450514 | 0.88 | LRRK2 (0.38) | SYKJAK2JAK3JAK1TYK2 | |
| SCHEMBL2482618 | 0.83 | KCNH3 (0.39) | SYKKCNH3JAK2JAK3TNK2 | |
| SCHEMBL2482765 | 0.83 | SYK (0.36) | SYKJAK2JAK3JAK1TYK2 | |
| SCHEMBL2447812 | 0.82 | LRRK2 (0.40) | SYKJAK2JAK3JAK1TYK2 | |
| SCHEMBL2446932 | 0.82 | SYK (0.46) | SYKJAK2JAK3JAK1TYK2 | |
| SCHEMBL2451543 | 0.81 | SYK (0.41) | SYKJAK2 | |
| SCHEMBL2445594 | 0.81 | SYK (0.39) | SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188101-B2 | Dihydropyridopyrimidines for the treatment of AB-related pathologies | ASTRAZENECA AB (SE) | 2012-05-29 | — | — | US | disclosed |
| EP-2367826-A1 | MODULATORS OF AMYLOID BETA. | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | disclosed |
| US-20100130495-A1 | COMPOUNDS 563 | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| WO-2010053438-A1 | MODULATORS OF AMYLOID BETA. | ASTRAZENECA AB (SE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130495-A1 | COMPOUNDS 563 | BACE1, PSEN1, PSEN2 | SYK 641/4885KCNH3 4816/4885JAK2 3639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.